Literature DB >> 10719668

The roles of surfactant proteins A and D in innate immunity.

P R Lawson1, K B Reid.   

Abstract

Research over the last decade on the surfactant proteins SP-A and SP-D suggests roles beyond surfactant lipid homeostasis, involving their participation in innate immune defence. SP-A and SP-D bind and agglutinate an impressive array of non-self structures, ranging from bacteria and fungi to allergens and environmental inorganic substrates. Complementing binding. SP-A and SP-D initiate and enhance immune cell ingestion and killing of targets. Recently, some exciting developments have extended and clarified their contributions to innate immunity. Knockout mice for SP-A and SP-D have been developed. The SP-A knockout confirms that SP-A plays a key role in defence against lung pathogens and reveals the underlying defense mechanisms that require SP-A. These surfactant proteins have also been shown to have important roles in modulating the immune response, instructing, yet quenching, the immune reactions in the lung. The crystal structure of SP-D plus functional studies with recombinantly altered forms of SP-A and SP-D has begun to characterise the structural motifs responsible for mediating their immune functions. Linkage and polymorphism analysis is explaining the role these genes may play in lung diseases and infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10719668     DOI: 10.1034/j.1600-065x.2000.917308.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  32 in total

Review 1.  Pulmonary surfactant: a front line of lung host defense.

Authors:  Jo Rae Wright
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  The innate immune system: gatekeeper to the female reproductive tract.

Authors:  Charles R Wira; John V Fahey
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

3.  The involvement of GM-CSF deficiencies in parallel pathways of pulmonary alveolar proteinosis and the alcoholic lung.

Authors:  William S Slovinsky; Freddy Romero; Dominic Sales; Hoora Shaghaghi; Ross Summer
Journal:  Alcohol       Date:  2018-07-18       Impact factor: 2.405

4.  Surfactant protein-B polymorphisms and mortality in the acute respiratory distress syndrome.

Authors:  Paul F Currier; Michelle N Gong; Rihong Zhai; Lucille J Pothier; Paul D Boyce; Lilian Xu; Chu-Ling Yu; B Taylor Thompson; David C Christiani
Journal:  Crit Care Med       Date:  2008-09       Impact factor: 7.598

5.  Anionic pulmonary surfactant phospholipids inhibit inflammatory responses from alveolar macrophages and U937 cells by binding the lipopolysaccharide-interacting proteins CD14 and MD-2.

Authors:  Koji Kuronuma; Hiroaki Mitsuzawa; Katsuyuki Takeda; Chiaki Nishitani; Edward D Chan; Yoshio Kuroki; Mari Nakamura; Dennis R Voelker
Journal:  J Biol Chem       Date:  2009-07-07       Impact factor: 5.157

6.  Lung infections and innate host defense.

Authors:  Ma Valdivia-Arenas; A Amer; Ln Henning; Md Wewers; Ls Schlesinger
Journal:  Drug Discov Today Dis Mech       Date:  2007

Review 7.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

8.  Characterization of Early Stages of Human Alveolar Infection by the Q Fever Agent Coxiella burnetii.

Authors:  Amanda L Dragan; Richard C Kurten; Daniel E Voth
Journal:  Infect Immun       Date:  2019-04-23       Impact factor: 3.441

9.  Surfactant dysfunction in SP-A-/- and iNOS-/- mice with mycoplasma infection.

Authors:  Judy M Hickman-Davis; Zhengdong Wang; German Alejandro Fierro-Perez; Patricia R Chess; Grier P Page; Sadis Matalon; Robert H Notter
Journal:  Am J Respir Cell Mol Biol       Date:  2006-08-17       Impact factor: 6.914

10.  Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

Authors:  J K van de Wetering; F E J Coenjaerts; A B Vaandrager; L M G van Golde; J J Batenburg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.